Literature DB >> 16946178

Predictors of relapse in a prospective study of fluoxetine treatment of major depression.

Patrick J McGrath1, Jonathan W Stewart, Frederic M Quitkin, Ying Chen, Jonathan E Alpert, Andrew A Nierenberg, Maurizio Fava, Jianfeng Cheng, Eva Petkova.   

Abstract

OBJECTIVE: Loss of response to a previously effective antidepressant is a common clinical problem. Retrospective analyses have shown that the pattern of response during antidepressant treatment (late onset and persistent versus other patterns) can be used to predict relapse during continuation and maintenance treatment and possibly to identify placebo responses to treatment. This study was designed to test the predictive value of response pattern prospectively and to examine the data for other predictors of relapse.
METHOD: Five hundred seventy persons with major depressive disorder were treated with fluoxetine for 12 weeks and their pattern of response was determined. Those who responded (N=292) underwent random assignment, under double-blind conditions, to continue taking fluoxetine or to switch to placebo for 52 weeks or until relapse. Survival analysis was used to examine the effect of covariates on relapse.
RESULTS: Although fluoxetine was significantly more effective than placebo during maintenance treatment, this chronically ill group had a high rate of relapse. Contrary to previous findings, a pattern of acute response was not predictive of relapse. Chronicity, symptom severity, a neurovegetative symptom pattern, and female gender were all associated with a significantly greater risk of relapse, with no difference observed between fluoxetine and placebo.
CONCLUSIONS: The pattern of response to acute treatment appears to be inconsistently predictive of relapse. There is a high rate of relapse with both active medication and placebo in patients with chronic depression. Illness characteristics predict loss of response both to fluoxetine and to placebo. No variable examined was predictive of differential relapse rates between fluoxetine and placebo.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16946178     DOI: 10.1176/ajp.2006.163.9.1542

Source DB:  PubMed          Journal:  Am J Psychiatry        ISSN: 0002-953X            Impact factor:   18.112


  31 in total

1.  Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.

Authors:  Stella Bitran; Amy H Farabaugh; Victoria E Ameral; Rachel A LaRocca; Alisabet J Clain; Maurizio Fava; David Mischoulon
Journal:  Int Clin Psychopharmacol       Date:  2011-07       Impact factor: 1.659

2.  Partitioning of Functional Data for Understanding Heterogeneity in Psychiatric Conditions.

Authors:  Eva Petkova; Thaddeus Tarpey
Journal:  Stat Interface       Date:  2009-01-01       Impact factor: 0.582

Review 3.  Rapid onset of true antidepressant action.

Authors:  Matthew J Taylor
Journal:  Curr Psychiatry Rep       Date:  2007-12       Impact factor: 5.285

Review 4.  Pharmacogenetics in psychiatry: are we ready for widespread clinical use?

Authors:  Maria J Arranz; Shitij Kapur
Journal:  Schizophr Bull       Date:  2008-08-27       Impact factor: 9.306

5.  A molecular pathway analysis of the glutamatergic-monoaminergic interplay serves to investigate the number of depressive records during citalopram treatment.

Authors:  Antonio Drago; Enrico Cocchi; Concetta Crisafulli; Alessandro Serretti
Journal:  J Neural Transm (Vienna)       Date:  2014-07-02       Impact factor: 3.575

6.  An Analysis of Relapse Rates and Predictors of Relapse in 2 Randomized, Placebo-Controlled Trials of Desvenlafaxine for Major Depressive Disorder.

Authors:  Roger S McIntyre; Rana S Fayyad; Christine J Guico-Pabia; Matthieu Boucher
Journal:  Prim Care Companion CNS Disord       Date:  2015-02-26

7.  Randomized trial of weekly, twice-monthly, and monthly interpersonal psychotherapy as maintenance treatment for women with recurrent depression.

Authors:  Ellen Frank; David J Kupfer; Daniel J Buysse; Holly A Swartz; Paul A Pilkonis; Patricia R Houck; Paola Rucci; Danielle M Novick; Victoria J Grochocinski; Deborah M Stapf
Journal:  Am J Psychiatry       Date:  2007-05       Impact factor: 18.112

8.  Residual sleep disturbance and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  Huaiyu Yang; Lara Sinicropi-Yao; Sarah Chuzi; Soo Jeong Youn; Alisabet Clain; Lee Baer; Ying Chen; Patrick J McGrath; Maurizio Fava; George I Papakostas
Journal:  Ann Gen Psychiatry       Date:  2010-02-26       Impact factor: 3.455

9.  Pharmacogenetics studies in STAR*D: strengths, limitations, and results.

Authors:  Gonzalo Laje; Roy H Perlis; A John Rush; Francis J McMahon
Journal:  Psychiatr Serv       Date:  2009-11       Impact factor: 3.084

10.  Type of residual symptom and risk of relapse during the continuation/maintenance phase treatment of major depressive disorder with the selective serotonin reuptake inhibitor fluoxetine.

Authors:  Huaiyu Yang; Sarah Chuzi; Lara Sinicropi-Yao; Dan Johnson; Ying Chen; Alisabet Clain; Lee Baer; Patrick J McGrath; Jonathan W Stewart; Maurizio Fava; George I Papakostas
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2009-07-02       Impact factor: 5.270

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.